Alemtuzumab

This page contains recent news articles, when available, and an overview of Alemtuzumab but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Alemtuzumab (when available)

Pharmacology and use:
Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. For treatment of B-cell chronic lymphocytic leukemia

Mechanism Of Action:
Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.

News Articles on Alemtuzumab

Genzyme to acquire worldwide rights of multiple sclerosis drug ...  -  ‎Mar 31, 2009‎
...(GENZ: News ) Tuesday announced an agreement with Bayer HealthCare to acquire the worldwide rights of Campath, or alemtuzumab. The deal will give Genzyme RTT News

Genzyme acquires rights to multiple sclerosis drug from Bayer  -  ‎Apr 2, 2009‎
Bayer will continue to fund a portion of alemtuzumab's development in multiple sclerosis (MS) and will retain an option to co-promote the product in MS upon Pharmaceutical Business Review

Company and People Notes: BMS and Otsuka Extend Abilify Agreement ...  -  ‎Apr 9, 2009‎
Bayer will continue to fund a portion of alemtuzumab's development in MS and will retain an option to copromote the product in MS upon approval. Pharmaceutical Technology Magazine

Biogen Idec Beats on Earnings but Misses on Revenues in Q1  -  ‎Apr 17, 2009‎
...while Phase III programs are under way with MS drugs alemtuzumab (Genzyme Corp. and Bayer AG), fingolimod (Novartis AG), dirucotide (BioMS Medical Corp. BioWorld Online

Monoclonal antibody cancer therapy  -  ‎Apr 5, 2009‎
Alemtuzumab (Campath) is an antibody drug approved for another type of leukemia, called B cell chronic lymphocytic leukemia (CLL). Alemtuzumab, based on an News-Medical.net

StandoutStocks.com: "Stocks that Standout" picks for today are ...  -  ‎Mar 31, 2009‎
Bayer will continue to fund a portion of alemtuzumab's development in MS and will retain an option to co-promote the product in MS upon approval. TMCnet

肾移�?�?�Alemtuzumab和Sirolimus治疗方案中Tacrolimus早期使用以防止 ...  -  ‎Apr 15, 2009‎
...医学空间（MEDcyber.com）4月16日消�?�—近期�?�表在《American Journal of Transplantation》上的一篇文章报�?�了异体肾移�?�?�Alemtuzumab诱导治疗和Sirolimus维�?治疗中医学空间

Genzyme adquiere la cartera de productos de oncología hematológica ...  -  ‎Apr 16, 2009‎
Bayer continuará financiando una parte del desarrollo de alemtuzumab en esclerosis múltiple y conservará la opción de promocionar conjuntamente el producto Mercado

Bayer verkauft Blutkrebs-Präparate an US-Konzern Genzyme  -  ‎Mar 31, 2009‎
Zudem vereinbarten Bayer und Genzyme, ihre Entwicklungskooperation bei dem Wirkstoff Alemtuzumab gegen Multiple Sklerose fortzusetzen. Reuters Deutschland

Siglato accordo strategico fra Genzyme e Bayer  -  ‎Apr 2, 2009‎
...“Alemtuzumab potrà diventare una terapia per il trattamento della Sclerosi Multipla, ed una parte importante del nostro futuro. Bologna 2000

Genzyme compra productos oncológicos de Bayer  -  ‎Apr 8, 2009‎
...sobre los derechos de desarrollo y distribución mundial de tres productos; Campath (alemtuzumab), Fludara (fludarabina) y Leukine (sargramostim). Invertia (Chile)

Genzyme acuerda la compra de dos productos al área de ...  -  ‎Apr 6, 2009‎
Supone así mismo una gran responsabilidad para Genzyme, que pasa a liderar los actuales ensayos clínicos con alemtuzumab de fase III en esclerosis múltiple Salut i Força

Wall Street schließt fest - GM-Wert in zwei Tagen halbiert  -  ‎Mar 31, 2009‎
...mehrerer Onkologie-Produkte von Bayer sowie die weitere Entwicklung und Vermarktung des Wirkstoffs "Alemtuzumab" gegen Multiple Sklerose (MS) getroffen. Frankfurter Allgemeine Zeitung

Wall Street mit Kurserholung erwartet  -  ‎Mar 31, 2009‎
...mehrerer Onkologie-Produkte von Bayer sowie die weitere Entwicklung und Vermarktung des Wirkstoffs "Alemtuzumab" gegen Multiple Sklerose (MS) getroffen. Frankfurter Allgemeine Zeitung

MS hastalığı için antikor üretildi  -  ‎Mar 31, 2009‎
Dr. Croze, bir tür monoklonal antikor (yapay antikor) olan Alemtuzumab’ın erken teşhiste kullanıldığında hastalığın yol açtığı özürlü durumun önüne Hürriyet

拜耳與Genzyme�?��?戰略�?�議  -  ‎Mar 31, 2009‎
...拜耳還將把雙方�?�作開發的多發性硬化症藥物Alemtuzumab的全�?�開發與分銷權利返還給Genzyme。該藥目�?�?處於開發階段。拜耳表示，兩公�?�將繼續它們在Alemtuzumab上的新浪網

DAX Schluss: Deutliche Erholung, Commerzbank mit an der Spitze  -  ‎Mar 31, 2009‎
Die beiden Unternehmen setzen ihre bestehende Entwicklungskooperation bei dem Wirkstoff Alemtuzumab gegen MS fort. Die Lizenz für die weltweite Vermarktung AktienCheck

Blick auf die Märkte  -  ‎Mar 31, 2009‎
...mehrerer Onkologie-Produkte von Bayer sowie die weitere Entwicklung und Vermarktung des Wirkstoffs „Alemtuzumab“ gegen Multiple Sklerose (MS) getroffen. Frankfurter Allgemeine Zeitung

New Guidelines Issued for Blood Cancer Treatment  -  18 Mar 2009
...use of Campath® (alemtuzumab) as a first-line therapy for the treatment of B-cell chronic lymphocytic leukemia (CLL) in its recent updated guidelines. PharmaLive.com (press release)

Application Submitted for New Drug to Treat Advanced Stage CLL  -  ‎Mar 2, 2009‎
The drug was 47% effective in patients resistant to fludarabine treatment and considered inappropriate candidates for alemtuzumab. Oncology Nursing News

Azaya Therapeutics Initiates Collaboration in Nanoparticle ...  -  ‎Mar 10, 2009‎
...several key executive positions with Ilex Oncology, Inc. and was instrumental in the development and approval of the ILEX drug, Campath (alemtuzumab). Nanotechwire.com

What do you know about new MS treatment?  -  ‎Feb 25, 2009‎
Campath 1H is the brand name of a monoclonal antibody known as alemtuzumab. This drug is used in treatment of B cell chronic lymphocytic leukemia (B-CLL) CNN

Stammzellentransplantation bei schubförmiger MS - ermutigende ...  -  ‎Feb 28, 2009‎
The Lancet Neurology publizierten Phase-Ib/IIa-Studie erhielten Patienten ein milderes Konditionierungsverfahren mit Cyclophophamid und Alemtuzumab bzw. Medizin-Aspekte

GSK and Genmab file biologics license application for leukemia drug  -  04 Feb 2009
...fludarabine and alemtuzumab treatment (fludarabine alemtuzumab refractory) and patients who were refractory to fludarabine and considered inappropriate Pharmaceutical Business Review

Research and Markets: Stakeholder Insight: Chronic Leukemias - Is ...  -  04 Feb 2009
Conversely, several factors have restricted uptake of Campath (alemtuzumab; Takeda/Genzyme/Bayer Schering). Gleevec is firmly established as the Trading Markets (press release),

Genmab, GSK Submit BLA for Arzerra in CLL  -  Jan 30, 2009
The BLA was based on an analysis that included 138 patients with CLL who showed limited or no response to treatment with fludarabine and alemtuzumab and TMCnet

Stem cells used to reverse MS  -  Jan 29, 2009
Last October, researchers from the University of Cambridge reported dramatic improvement in the condition of MS sufferers treated with alemtuzumab, Independent,

GSK And Genmab Submit Arzerra (Ofatumumab) Application To FDA For ...  -  Feb 2, 2009
The submission is based on an analysis that included 138 patients with CLL who showed limited or no response to both fludarabine and alemtuzumab treatment Medical News Today (press release),

New studies hopeful for multiple sclerosis  -  Jan 21, 2009
The first study looked at a drug called alemtuzumab. It's a drug already used to treat a blood cancer called leukaemia. It works on the immune system. guardian.co.uk,

The American Society of Clinical Oncology 2008: Advances in ...  -  Feb 2, 2009
Alemtuzumab is the most effective agent in terms of efficacy for the treatment of patients with CLL who have failed both alkylating agents and fludarabine. Cancer Consultants,

Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth  -  Jan 13, 2009
The growing use of Campath ® (alemtuzumab) as a first-line treatment for B-cell chronic lymphocytic leukemia will also be a driver of long-term growth in WELT ONLINE,

Buzz around Campath proof-of-concept trial in MS  -  Jan 16, 2009
But whether Campath (alemtuzumab), a monoclonal antibody (mAb) already approved to treat leukemia, actually 'reverses' MS, as some news stories in the Nature.com (subscription),

Dear Jeremy  -  Jan 16, 2009
Now, having been given the drug Alemtuzumab, I have not had an attack since 2005, I hardly ever use a wheelchair, my vision is 20/20, my hands have regained guardian.co.uk,

Hematopoietic Stem Cells Show Promise for Relapsing-Remitting MS  -  Jan 29, 2009
The conditioning regimen for the cells consisted of 200 mg/kg cyclophosphamide and either 20 mg alemtuzumab (Campath) or 6 mg/kg rabbit antithymocyte MedPage Today,

The American Society of Clinical Oncology 2008: Highlights of ...  -  Jan 30, 2009
Alemtuzumab (Campath) is very effective for the treatment of patients with CLL who have failed both alkylating agents and Fludara. Cancer Consultants,

Reduced-intensity Allogeneic Stem Cell Transplants Effective for ...  -  Jan 20, 2009
Patients in this study received a Campath® (alemtuzumab), Fludara® (fludarabine), and melphalan regimen. Thirty-two percent of patients relapsed, Cancer Consultants,

Stammzellen: Ermutigende Ergebnisse im Frühstadium der multiplen ...  -  Jan 30, 2009
Die non-myeloablative Konditionierung wurde mit Cyclophosphamid, Alemtuzumab und Antithymozytenglobulin durchgeführt. In den folgenden 24 bis 48 Monaten hat Deutsches Ärzteblatt,

Fármaco para la esclerosis múltiple  -  Jan 11, 2009
El fármaco Alemtuzumab parece frenar la progresión de la enfermedad en pacientes que están en el primer estadio activo de recaída y remisión de EM - la Diario de Madryn,

Des cellules souches contre la sclérose en plaques  -  Jan 30, 2009
...dont le Natalizumab commercialisé en France et bientôt, s'il obtient son autorisation de mise sur le marché, l'Alemtuzumab qui réduit de 74 % le nombre Le Figaro,

Τα οφέλη της π�?ώιμης θε�?απείας  -  Jan 13, 2009
...-*Π�?όσφατα υπή�?ξαν ανακοινώσεις σχετικά με μια καινο�?�?για θε�?απεία για την Πολλαπλή Σκλή�?υνση, το alemtuzumab. Θα θέλατε να μας πείτε γι' αυτήν; «�?αι, Ελευθε�?οτυπία,

Genmab A/S: Arzerra(TM) (Ofatumumab) Demonstrates High Response ...  -  Dec 8, 2008
The analysis included 138 patients with CLL who showed limited or no response (refractory) to both fludarabine and alemtuzumab treatment (double refractory; MarketWatch

Genzyme Reports Clolar® Data Further Supporting Potential of ...  -  Dec 8, 2008
Three studies, including one oral presentation, showed that Campath ® (alemtuzumab), as a single agent and in combination therapy, offered strong overall WELT ONLINE,

Genmab Shares Rise on Ofatumumab CLL Data  -  Dec 9, 2008
The analysis draws on data concerning 138 CLL patients, who exhibited little or no response to both fludarabine and alemtuzumab treatment (n = 59) and BioWorld Online,

Three Studies Presented at the American Society of Hematology ...  -  Dec 9, 2008
The multicenter trial evaluated subcutaneous alemtuzumab given three times weekly at 30 mg in fludarabine refractory CLL. From September 2002 to February SYS-CON Media,

Treatment Updates  -  Dec 23, 2008
...may become a new treatment option for CLL patients who progress on other therapies, including Fludara (fludarabine) and Campath (alemtuzumab). Curetoday.com (press release),

New drugs to battle multiple sclerosis  -  Dec 12, 2008
Another compound on the horizon is alemtuzumab (Campath), a monoclonal antibody designed and FDA-approved for fighting leukemia. In a trial of 334 patients Los Angeles Times,

Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, Effecitive in CLL  -  Dec 10, 2008
Ofatumumab (JuMax-CD-20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or Cancer Consultants,

FDA Approves Genzyme's Mozobil  -  Dec 15, 2008
Genzyme's drugs Campath(R) (alemtuzumab) and Thymoglobulin(R) (Anti-thymocyte Globulin [Rabbit]) are also used in the hematology/oncology setting. MarketWatch

Single-Agent Ofatumumab Produces Response in Treatment-Refractory ...  -  Dec 11, 2008
Prognosis is poor for patients with CLL that is refractory to fludarabine and alemtuzumab and for patients with bulky lymphadenopathy (>5 cm) that is DG News

Romidepsin Active for Treatment of Refractory Cutaneous T-Cell ...  -  Dec 17, 2008
...alemtuzumab, and the usual chemotherapy given for non-Hodgkin’s lymphoma including doxorubicin. However, none of these therapies are curative. Cancer Consultants,

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R ...  -  Dec 5, 2008
WAYNE, NJ, Dec 05, 2008 /PRNewswire via COMTEX/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data on Campath(R) (alemtuzumab) and MarketWatch

Rituxan® and High-dose Methylprednisolone Effective Initial ...  -  Dec 9, 2008
Six patients received Campath® (alemtuzumab) as consolidation, and five were rendered negative for minimal residual disease. The overall survival with a Cancer Consultants,

Three Studies Presented At The American Society Of Hematology ...  -  Dec 10, 2008
Bayer HealthCare Pharmaceuticals Inc. announced results from three studies showing that treatment with Campath(R) (alemtuzumab) showed activity in high-risk Medical News Today (press release),

Genta: Genasense suffers further setback  -  Dec 4, 2008
Currently, FCR - fludarabine, cyclophosphamide and Rituxan (rituximab; Biogen Idec/Genentech/Roche/Zenyaku Kogyo) and Campath (alemtuzumab; Trading Markets (press release),

Stakeholder Insight - Chronic Leukemias - Is there room left for ...  -  Dec 5, 2008
Conversely, several factors have restricted uptake of Campath (alemtuzumab; Takeda/Genzyme/Bayer Schering). Gleevec is firmly established as the PR-Inside.com (Pressemitteilung),

Multiple Sklerose: Verringerung des Schubrisikos unter neuem ...  -  Dec 8, 2008
Multiple Sklerose: Alemtuzumab ist ein humanisierter, monoklonaler Antikörper, der selektiv an ein spezielles Ziel, das CD52-Antigen auf der Zelloberfläche Medizin-Aspekte,

Un anticorps contre la sclérose en plaque  -  Dec 15, 2008
De fait, lors d’un essai clinique, l’alemtuzumab a réduit de 71 % le risque des malades de développer un handicap supplémentaire [1]. La Recherche,

Empresas.-'Arzerra'(GSK/Genmab) ofrece altas tasas de respuesta ...  -  Dec 11, 2008
...tratamiento con fludarabina y con alemtuzumab (doble refractarios), o que eran refractarios a fludarabina y no eran candidatos a recibir alemtuzumab por elEconomista.es,

1.Forschungswerkstatt Multiple Sklerose von Bayer Schering Pharma  -  Dec 4, 2008
Alemtuzumab - ein bisher einmaliger Therapieeffekt Mit Alemtuzumab, einem humanisierten Antikörper gegen CD52 aus der Pipeline von Bayer Schering, lifepr.de (Pressemitteilung),

Revue des sciences (12/08)  -  Dec 1, 2008
Un médicament développé il ya trente ans pour traiter des leucémies, l'alemtuzumab, représente aujourd'hui un espoir face à la sclérose en plaques, Transversales Sciences Culture,

Terapias de rescate en leucemia  -  Dec 10, 2008
...a dos terapias clásicas contra este mal:la combinación de fludarabina y alemtuzumab o fludarabina sola sin posibilidad de administrar el segundo fármaco Rioja2.com | Diario digital ,

Brand Names/Synonyms:
Alemtuzumab is also known by the following brand names and/or synonymsCampath; Campath (ILEX Pharmaceuticals LP)

Drug Category:
Alemtuzumab is categorized under the following by the FDA: Antineoplastic Agents

Dosage Forms:
Not Available

Absorption:
Not Available

Interactions:
Not Available

Chemical IUPAC Name:
Humanized anti-CD52 antibody

:

Web health.mongabay.com/health

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.